Top Banner
Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 1 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29 Alpha Recycling in Confirmatory Clinical Trials Unifies, Simplifies, Extends many common MTPs Olivier Guilbaud Senior Principal Scientist AstraZeneca R&D, Södertälje, Sweden
29

Alpha Recycling in Confirmatory Clinical Trials

Feb 25, 2016

Download

Documents

kin

Unifies, Simplifies, Extends many common MTPs. Alpha Recycling in Confirmatory Clinical Trials. Olivier Guilbaud Senior Principal Scientist AstraZeneca R&D, Södertälje, Sweden. Outline . Background. Splitting, Recycling, Adding, (parts of alpha). Graphs and Default Graphs for MTPs . - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

1

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Alpha Recyclingin

Confirmatory Clinical TrialsUnifies, Simplifies, Extends

many common MTPs

Olivier GuilbaudSenior Principal Scientist

AstraZeneca R&D, Södertälje, Sweden

Page 2: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

2

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Outline

• Background

• Splitting, Recycling, Adding, (parts of alpha)

• Graphs and Default Graphs for MTPs

• Rejection Algorithm

• Holm’s MTP for groups of Hs, and a problem to discuss

• Improvements through extensions of the Default Graph

• Summary, and further results:

• (Simultaneous Confidence regions, CTP-formulation of MTPs)

Page 3: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

3

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Background: Regulatory environment

Citation from EMEA/CPMP’s (2002) Points to Consider on Multiplicity Issues in Clinical Trials :

“ … multiplicity can have a substantial influence on the rate of false positive conclusions …”

”As a general rule it can be stated that control of the family-wise type-I error rate in the strong sense … is a minimal prerequisite for confirmatory claims”

Page 4: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

4

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Background: Multiple Confirmatory Comparisons

• Several Efficacy Variables • Several Tolerability Variables • Several Comparators (e.g. Placebo, Active 1, Active 2,

…)• Several Doses

• Delta-Noninferiority / Superiority / Delta-Superiority • Several Subgroups/Kinds of Subjects

• Several kinds of Administration (e.g. once daily, twice daily, …)

Confirmatory:Pre-specified family of multiple comparisons (i.e. statistical tests) .Risk of getting any ”false positive” result/conclusion is (no matter how many or which H0s are true – Strong Control)

Page 5: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

5

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Background: Abbreviations/Terminology

• MTP : Multiple Testing Procedure

• MCP : Multiple Comparison Procedure

• FWER : Family-Wise Error Rate (type-I errors) =Pr[at least 1 true Hi in the Family is rejected by the

MTP](to be controlled to be in the strong sense)

, no matter how many, or which, His in the family are true

In contrast to the weak sense (old) : , if all His in the family are true

Page 6: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

6

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Background: brief refresher about three basic MTPs

Three basic MTPs for Family {H1, H2, H3} based on raw p-values p1, p2, p3

• Holm MTP (1979)p(1) /3, p(2) /2, p(3) /1

• Fixed-Sequence MTP (old) p1 , p2 , p3

• Fallback MTP (2003/2005)weights w1, w2, w3 p1 w1, p2 (w2+), p3 (w3+)

Now, to the Alpha-Recycling framework

Page 7: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

7

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Two articles in Statistics in Medicine, February 2009

Only this now

Page 8: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

8

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Idea: Splitting and Recycling test-mass (= part of )

Bonferroni:

split of Fixed-Sequence: recycling of Combination of

split & recycling of

Throughout: Raw p-value available for each null hypothesis H

Page 9: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

9

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Idea: Adding test-mass from different paths

Parallel-gatekeeping MTP: 2 graphs for same MTP

Default graph

Important for rejection AlgorithmIts sequences reflect the possible rejection paths

Page 10: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

10

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Idea: Adding test-mass from different paths

Fallback MTP for 3 Hs: 2 graphs for same MTP

Default graph

Important for rejection AlgorithmIts sequences reflect the possible rejection paths

Page 11: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

11

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Idea: Adding test-mass from different paths

Holm’s MTP for 3 Hs: 2 graphs for same MTP

Default graph

Important for rejection AlgorithmIts sequences reflect the possible rejection paths

Page 12: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

12

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Rejection Algorithm - based on Default-Graph Seqs

This MTP controls (in the strong sense) the FWER to be !

Step 1. For each ”first” H in Sequences,

(a) add-upp test mass from ”its” Sequences(b) test H at this added-up level

If nothing is rejected, then Stop; otherwise:

Reduce Sequences by deleting all rejected H from Sequences, and go to Step 2 with remaining reduced Sequences

Step r = 2, 3, …. For each ”first” H in remaining reduced Sequences,

(a) add-upp test mass from ”its” Sequences(b) test H at this added-up level

If nothing is rejected, then Stop; otherwise:

Reduce Sequences by deleting all rejected H from Sequences, and go to Step r + 1 with remaining reduced Sequences

Page 13: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

13

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Comments

• number of sequences can be increased(no restriction)

• length of sequences can be increased(no restriction)

• if not all sequences contain all Hs, thenimprovements are possible (by increasing length of relevant sequences)

• interpretability of MTP is important(also when improvements are considered)

Page 14: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

14

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

A refresher – Bonferroni & Holm for groups of Hs

Step1: Bonferroni-version as above

Step2: If one group is entirely rejected, but not the other, then try again

in the other at increased level

1 2

3 4

Bonferroni for 2 groups of 2 Hs, with

Fixed-Seq testing within group

/2 /2

Holm for 2 groups of 2 Hs, with Fixed-Seq testing within group:

1 2

3 4

/2 /2

1

1 2

3 4

/2

1

Page 15: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

15

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Problem to discuss with your neighbour

1 2

3 4

Bonferroni for 2 groups of 2 Hs, with

Fixed-Seq testing within group

/2 /2

(is already in default-graph form):

Extend sequences of default graph to get recycling improvement equivalent toHolm for 2 groups of 2 Hs, with Fixed-Seq testing within group

1 2

3 4

/2 /2

Page 16: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

16

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Recent Example discussed by FDA statisticians

• Confirmatory family with 4 null hypotheses :

H1 = (Null hypothesis concerning non-inferiority for primary variable) H2 = (Null hypothesis concerning superiority for primary variable) H3 = (Null hypothesis concerning non-inferiority for secondary variable) H4 = (Null hypothesis concerning superiority for secondary variable)

H1

H2 H3

H4

w (1-w)

Page 17: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

17

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Recent Example discussed by FDA statisticians

Alpha-recycling applied to show Non-inf & Superiority for Primary & Secondary Variables

H1

H2 H3

H4

w (1-w)

Basic version

H1

H2 H3

w (1-w)

H1

H4

Reformulation in Recycling terms

Very easy to test with rejection algorithm !

But why not recycle also after the last H in each sequence ?

Page 18: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

18

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Recent Example discussed by FDA statisticians

Alpha-recycling applied to show Non-inf & Superiority for Primary & Secondary Variables - Simple improvement

Improvement Reformulation in Recycling terms

H1

H2 H3

w (1-w)

H1

H4H3

H2H4

H1

H2 H3

H4

w (1-w)

Very easy to test with rejection algorithm !This improved MTP is ”-exhaustive” !

May be questionedby some (not me)!

May be questionedby some (not me)!

Page 19: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

19

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Sequences can be extended/added for more rejections

Improved Fallback MTP for 3 Hs: 2 graphs for same MTP

Default graph

This improved MTP is ”-exhaustive” !

Page 20: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

20

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Sequences can be extended/added for more rejections

Improved Parallel-gatekeeping : 2 graphs for same MTP

Default graph

This improved MTP is ”-exhaustive” !

Page 21: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

21

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

XXX example: 2 primary & 2 second vars, 2 age stata

1

2 3

4

5 6

8

9 11

7

10 12

Original proposal

Simple improvement possible ( Holm instead of Bonf after H8 ):

Add sub-seq (11, 12) to Default-graph sequences ending with (9, 10) Add sub-seq (9, 10) to Default-graph sequences ending with (11, 12)

1

2

7

8

9

10

/81

3

7

8

9

10

/84

5

7

8

9

10

/84

6

7

8

9

10

/81

2

7

8

11

12

/81

3

7

8

11

12

/84

5

7

8

11

12

/84

6

7

8

11

12

/8

Default graphReformulation in Recycling terms

to show strong control of FWER

Page 22: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

22

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Compact notation for MTP in XXX example

1

2 3

4

5 6

8

9 11

7

10 12

Original proposal

Compact notation for this recycling MTP (B here is Bonf-operator):

B(H1 B(H2, H3), H4 B(H5, H6)) H7 H8 B(H9 H10, H11 H12)

Can be expanded (using certain rules) to 8 sequences of Hs above

1

2

7

8

9

10

/81

3

7

8

9

10

/84

5

7

8

9

10

/84

6

7

8

9

10

/81

2

7

8

11

12

/81

3

7

8

11

12

/84

5

7

8

11

12

/84

6

7

8

11

12

/8

Default graphReformulation in Recycling terms

Page 23: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

23

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

YYY example: 3 doses vs. 0, 1 primary & 1 second var

1

3

1

5

2

5

2

4

6 6

/4 /4 /4 /4

Reformulation in Recycling termsDefault graph

1 2

3 45

6

Basic version

/2 /2

Idea: To give lowest dose a chance if at least 1 of the 2 larger doses works for the primary variable

Page 24: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

24

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

YYY example – Improvement 1

1

3

1

5

2

5

2

4

6 6

/4 /4 /4 /4

Reformulation in Recycling termsDefault graph

5

6

5

6

1 2

3 45

6

Improvement 1

/2 /2

Increases level for H5 and H6 if H3 and/or H4 are rejected

Page 25: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

25

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

YYY example – Improvement 2

1 2

3 45

6

Improvement 2

1/2 1/2

Gives H1 or H2 a (Holm-type) second opportunity to be rejected if not rejected initially

1

3

1

5

2

5

2

4

6 6

/4 /8 /8 /4

Reformulation in Recycling termsDefault graph

5

6

5

6

1

5

6

/8

2

5

6

/8

2

4

2 2

4

1 1

3 1

3

3

4 3

4

3 4

Page 26: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

26

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Summary, and further results

• Easy to formulate (cf. Closed-Testing Pocedures) • Easy to perform (even manually)

• Easy to calculate multiplicity-adjusted p-values (algorithm similar to that for rejections)

• Easy to obtain weights of Bonferroni test for any intersection hypothesis HI of corresponding CTP(useful for contruction of Conf regions)

• Easy to construct new MTPs (for new problems)

• Unifies many common MTPs

• Compact algebraic notation available(to describe and derive default graphs)

Page 27: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

27

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Corresponding Simultaneous Confidence Regions ???

• Holm MTP (1979)p(1) /3, p(2) /2, p(3) /1

• Fixed-Sequence MTP (old) p1 , p2 , p3

• Fallback MTP (2003/2005)weights w1, w2, w3 p1 w1, p2 (w2+), p3 (w3+)

Solution inJASA 1999

Open until2007

Three basic MTPs for Family {H1, H2, H3} based on raw p-values p1, p2, p3

Page 28: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

28

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Corresponding Simultaneous Confidence Regions !!!

Amazing:

Simultanouslypresented at MCP 2007in Vienna

28 years after Holm (1979)

ExtensionsandRelations

Confidence regions require weights that can be obtained directly from rejection algorithm of recycling approach

Page 29: Alpha Recycling in Confirmatory Clinical Trials

Proprietary and Confidential © AstraZeneca 2009FOR INTERNAL USE ONLY

34

O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29

Outline

• Background

• Splitting, Recycling, Adding, (parts of alpha)

• Graphs and Default Graphs for MTPs

• Rejection Algorithm

• Holm’s MTP for groups of Hs, and a problem to discuss

• Improvements through extensions of the Default Graph

• Summary, and further results:

• (Simultaneous Confidence regions, CTP-formulation of MTPs)